Nearing All-Time Highs
OKYO Pharma LTD (AIM:OKYO) Interim Results for the Six Months Ending 30 September 2022
OKYO Pharma Limited (LSE: OKYO, NASDAQ: OKYO),— an ophthalmology-focused bio-pharmaceutical company developing OK-101 to treat Dry Eye Disease (DED) to address the significant unmet need in this multi-billion-dollar market, today
OKYO Pharma Limited (AIM:OKYO) U.S. FDA Clearance of IND Application for OK-101
OKYO Pharma Announces U.S. FDA Clearance of IND Application for OK-101 for the Treatment of Dry Eye Disease
OKYO Pharma Limited (AIM:OKYO) OKYO to Participate at Biotech Showcase
London and New York, NY., 21 December, 2022 – OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to
OKYO Pharma LTD (AIM:OKYO) publicly files a registration statement with the SEC
LONDON and NEW YORK, Dec. 06, 2022 (GLOBE NEWSWIRE) — OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease
OKYO Pharma LTD (AIM:OKYO) Announces U.S. IND Filing on OK-101 for the Treatment of Dry Eye Disease
OK-101 first-in-human Phase 2 trial will incorporate primary and secondary efficacy endpoints characterizing signs and symptoms of Dry Eye Disease-
OKYO Pharma (NASDAQ: OKYO; LSE: OKYO) Interview to Air on Bloomberg U.S. on the RedChip Money Report®
NEW YORK and LONDON, Sept. 08, 2022 (GLOBE NEWSWIRE) — OKYO Pharma Limited (NASDAQ: OKYO; LSE: OKYO;), a biotechnology company focused on the discovery and development of novel molecules to
OKYO Pharma LTD (AIM: OKYO) announces issuance of U.S. Patent No. 11,254,720
Covering OKYO’s dry eye drug candidate OK-101 for use to treat ocular neuropathic pain.
OKYO Pharma Limited (OKYO.L) IND filing Q3 2022 and Phase 2 initiation Q4 2022
OKYO to File IND in Q3 2022 for OK-101 to treat Dry Eye Disease (“DED”) and to go directly to a Phase 2 Human Clinical Efficacy Trial in DED Patients
Deepmatter Competitor PathAI Welcomed by Roche into its open digital pathology initiative
Roche has selected PathAI to collaborate with it on an artificial intelligence program that will be merged with its digital pathology work.
OKYO Pharma LTD (OKYO.L) Announces final audited results for the year ended 31 March 2021
LONDON, Aug. 02, 2021 (GLOBE NEWSWIRE) — OKYO Pharma Limited (the “Company”) is pleased to announce its final audited results for the year ended 31 March 2021.